bruno vincenzi
bruno vincenzi
Unknown affiliation
Verified email at unicampus.it
Title
Cited by
Cited by
Year
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective …
W De Roock, B Claes, D Bernasconi, J De Schutter, B Biesmans, ...
The lancet oncology 11 (8), 753-762, 2010
19822010
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
F Loupakis, A Ruzzo, C Cremolini, B Vincenzi, L Salvatore, D Santini, ...
British journal of cancer 101 (4), 715-721, 2009
5662009
Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients
D Santini, B Vincenzi, G Dicuonzo, G Avvisati, C Massacesi, F Battistoni, ...
Clinical Cancer Research 9 (8), 2893-2897, 2003
3662003
Pamidronate induces modifications of circulating angiogenetic factors in cancer patients
D Santini, B Vincenzi, G Avvisati, G Dicuonzo, F Battistoni, M Gavasci, ...
Clinical Cancer Research 8 (5), 1080-1084, 2002
3182002
Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients
C Raimondi, A Gradilone, G Naso, B Vincenzi, A Petracca, C Nicolazzo, ...
Breast cancer research and treatment 130 (2), 449-455, 2011
2692011
High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice
D Santini, F Loupakis, B Vincenzi, I Floriani, I Stasi, E Canestrari, E Rulli, ...
The oncologist 13 (12), 1270-1275, 2008
2632008
Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB–IIA non-small cell lung cancer
TC Mineo, V Ambrogi, A Baldi, C Rabitti, P Bollero, B Vincenzi, G Tonini
Journal of clinical pathology 57 (6), 591-597, 2004
2622004
The antineoplastic role of bisphosphonates: from basic research to clinical evidence
D Santini, U Vespasiani Gentilucci, B Vincenzi, A Picardi, F Vasaturo, ...
Annals of Oncology 14 (10), 1468-1476, 2003
2002003
Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in …
D Santini, B Vincenzi, S Galluzzo, F Battistoni, L Rocci, O Venditti, ...
Clinical Cancer Research 13 (15), 4482-4486, 2007
1922007
Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy
A Ruzzo, F Graziano, K Kawakami, G Watanabe, D Santini, V Catalano, ...
J Clin Oncol 24 (12), 1883-1891, 2006
1792006
Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib
B Vincenzi, D Santini, A Russo, R Addeo, F Giuliani, L Montella, S Rizzo, ...
The oncologist 15 (1), 85, 2010
1772010
Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients
B Vincenzi, D Santini, G Dicuonzo, F Battistoni, M Gavasci, A La Cesa, ...
Journal of interferon & cytokine research 25 (3), 144-151, 2005
1682005
Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients
D Santini, G Schiavon, B Vincenzi, L Gaeta, F Pantano, A Russo, ...
PloS one 6 (4), 2011
1612011
Emerging anti-cancer molecular mechanisms of aminobisphosphonates
M Caraglia, D Santini, M Marra, B Vincenzi, G Tonini, A Budillon
Endocrine-related cancer 13 (1), 7-26, 2006
1482006
Fever after zoledronic acid administration is due to increase in TNF-α and IL-6
G Dicuonzo, B Vincenzi, D Santini, G Avvisati, L Rocci, F Battistoni, ...
Journal of interferon & cytokine research 23 (11), 649-654, 2003
1432003
Circulating tumor cells (CTCs) in metastatic breast cancer (MBC): prognosis, drug resistance and phenotypic characterization
A Gradilone, G Naso, C Raimondi, E Cortesi, O Gandini, B Vincenzi, ...
Annals of Oncology 22 (1), 86-92, 2011
1412011
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?
D Santini, B Vincenzi, R Addeo, C Garufi, G Masi, M Scartozzi, A Mancuso, ...
Annals of Oncology 23 (9), 2313-2318, 2012
1342012
Expression pattern of receptor activator of NFκB (RANK) in a series of primary solid tumors and related bone metastases
D Santini, G Perrone, I Roato, L Godio, F Pantano, D Grasso, A Russo, ...
Journal of cellular physiology 226 (3), 780-784, 2011
1282011
Cetuximab: from bench to bedside
B Vincenzi, A Zoccoli, F Pantano, O Venditti, S Galluzzo
Current cancer drug targets 10 (1), 80, 2010
1252010
Genetic modulation of the Let-7 microRNA binding to KRAS 3′-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab–irinotecan
F Graziano, E Canestrari, F Loupakis, A Ruzzo, N Galluccio, D Santini, ...
The pharmacogenomics journal 10 (5), 458-464, 2010
1242010
The system can't perform the operation now. Try again later.
Articles 1–20